A. M. G. M. Gonzalez-Angulo, J. L. Murray, et al., “Open Label Randomized Clinical Trial of Standard Neoadjuvant Chemotherapy with Paclitaxel Followed by FEC (TFEC) vs the Combination of Paclitaxel and RAD001 Followed by FEC (TR-FEC) in Women with Triple Receptor-Negative Breast Cancer (TNBC),” American Society of Clinical Oncology Annual Meeting, Chicago, 3-7 June 2011.

has been cited by the following article:

• TITLE: The Role of Everolimus in the Treatment of Breast Cancer

  AUTHORS: José Pablo Leone, Ricardo H. Álvarez

  KEYWORDS: Advanced Breast Cancer; Everolimus; mTOR Inhibitors

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.7, August 19, 2013

  ABSTRACT: The development of resistance to chemotherapy, endocrine therapy and anti HER2 agents in breast cancer is an important and common problem that impacts in the management of patients, particularly in the metastatic setting. This resistance has been explained in part by the activation of signal transduction pathways, including the PI3K/AKT/mTOR. The blockade with mTOR inhibitors such as everolimus is a new target agent for therapy that attempts to enhance treatment efficacy and restore tumor sensitivity. In this review article, we present the data about the use of everolimus for the treatment of breast cancer in all tumor phenotypes. Future studies that evaluate biomarkers for treatment response are needed to identify the specific populations that have the highest benefit of this new targeted therapy.